| Useful Advices |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Business > Reverse Merger, IPO Or Direct Public Offering (DPO), Which One Is Right For You? |
|
Useful Advices - Reverse Merger, IPO Or Direct Public Offering (DPO), Which One Is Right For You?
A direct public offering is when a company raises capital by selling its shares directly to what is refer to as affinity groups, unlike an IPO which are sold by a broker dealer to its customers and the general public through other broker dealers who have customers intereste According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product d in buying shares in the company. In IPO’s you have a firm commitment underwriting, where the underwriters promise to purchase the securities for their own account if they can not sell them to customers. Best-effort underwriting: The underwriters do not guarantee any sp ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in cific number of shares to be sold, they merely act as brokers. In an IPO the lead underwriter is refer to as the syndicate manager, he keeps the book and invites other broker dealers to join the syndicate. In an firm commitment underwriting, an eastern underwriters agreem lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. ent makes members liable for any unsold securities, regardless of how much of their allotment they sold. The eastern underwriting agreements have joint and several liability. A western underwriting a agreement: In a firm commitment underwriting, it makes underwriters liab here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe e severally but not jointly. If one syndicate member can not sell its entire allotment, only he must buy the unsold securities. In a direct public offering the company sells the shares to affinity groups, who fall in this category? Customers, suppliers, distributors, fri d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro ends, employees and other members the community. In a direct public offering the company place its shares in the hand of those people who are familiar with the company and know the company’s product and management, and are most likely to hold the shares longer because they ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc feel comfortable with the company’s prospects for the future. Direct public offerings are considerably less expensive than IPO’s and most effective for smaller offerings, for large offerings the sales staff and customer base of a broker dealer are usually necessary. Sinc easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi e the affinity group is already familiar with the company and its practices it doesn’t put pressure on the company to change the way it does business, and will remain loyal to the company because of it’s presence in the community. DPO’s are preferable to venture capital fi nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically ancing because it allows the present management to execute its business plan without outside interference. When a small company turns to a single large investor they tend to surrender the freedom to make all the decisions. In a DPO like other method of going public today a and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ udited financial statements are required, unlike a reverse merger you choose your shareholders and you don’t have to deal with shady, unscrupulous shell owners. Shell owners usually keep between 5-15% of the shares outstanding and are quick to liquidate, and besides they d ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi not have an interest in the well being of the company’s share price. Even if you insert a stipulation in the contract that they can not sell for a year they will find a way of shorting the stock and destroying the share price. This make DPO a preferable option even for c ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a mpanies that don’t need financing but would like to go public. If you are in the kind of business that keep records of your customer in order to bill them or for follow ups you already have a head start. You must be able to contact those affinity group in order to market t dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod he shares to them, a popular business that has a lot of client but does not have the contact information is at disadvantage because it’s unable to contact its
customer. There are other ways to market the company’s stock for example a medical supply company might try conta cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin ting doctor in the area or by purchasing a mailing list. But the best way is when you have an established relationship with your affinity group and are in constant contact with them, by mail, newsletter, or email. Sometime a supplier or distributor may want to purchase an tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen interest in the company in order retain the business and keep competitors from stealing the client. A DPO does not always require audited financials but if you plan on going public you will need them. So you must hire an auditing firm. A foreign company must use a Certifi t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel d International Accounting Firm. A good Attorney that has experience with Direct Public Offerings, one that is familiar with the process and does not have to waste time researching and learning. You must prepare sales material that provides a good deal of information abou ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust t the company, you want investors feel that your company has a future. You should always have a business plan, it will show investor that you have strategy for making the company succeed and doing it one step at a time. By setting dates for the implementation of each st y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products p in your plan it shows investors that you have things well under control, but allow some time in case you must make adjustments. If you wish to take your company public then you must file a form SB with the Securities and Exchange Commission and a form 15c211 must be file . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de d with the NASD. A DPO is an alternative to an IPO or Reverse Merger for a company wishing to go public or obtain financing, it allows the company owner(s) to call the shots instead of an underwriter or a shell owner. We assist companies in going public through Reverse Me elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip ger, DPO and assist them in finding an underwriter if the company prefers and IPO. Which one is right for you? We can help you decide. For additional information visit our website: www.genesiscorporateadvisors.com email: josephquinones@genesiscorporateadvisors.co tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Security Guards For Your Peace Of Mind A Secret Of Business Growth - Pick Passionate External People What You Need To Start Your Own Business
|